Fundraising FoxAimmune Therapeutics
Unicorn exit · $2.6BAcquired4 known investors
Find your way into Aimmune Therapeutics
Sign up to see every warm intro you have to Aimmune Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aimmune Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Nestlé Health Science August 2020 · $2.6B (approximately $2.6 billion, $34.50 per share in cash) · source ↗
Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.
Investors · 4
How we know: Aisling Capital's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Founder mafia
2 people who came through Aimmune Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Aimmune Therapeutics do?
- Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.
- Who are Aimmune Therapeutics's investors?
- Aimmune Therapeutics's investors include Aisling Capital, Foresite Capital, Longitude Capital, Menlo Ventures.